NR3C2 and heart failure: Mineralocorticoid receptor antagonists (MRA): Spironolactone and eplerenone (steroidal MRAs) reduce hospitalizations and mortality in patients with heart failure with reduced ejection fraction [222, 223]. Finerenone (non-steroidal MRA) reduces heart failure-related hospitalizations and improves kidney outcomes in patients with diabetic kidney disease [224, 225];